Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer ...

Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes ...

French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). | French ...

Philips has secured an FDA clearance for what it describes as the world’s first imager to combine spectral CT with ...

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...

Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three ...

Last month, the NIH announced that it had found evidence of research misconduct by Eliez | This week on "The Top Line," we ...

Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

The two companies have been working together since 2017, and, in 2021, they agreed to collaborate on NM26, a bispecific ...

The FDA has granted a de novo clearance to a wearable device—with a form factor you’re familiar with—that can check patients ...

Gene therapy for some diseases, including Duchenne muscular dystrophy (DMD), can be tricky because the needed gene is often ...